Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients
Apolipoprotein E Mimetic Peptide CN-105 und postoperatives Delir bei älteren Patient:innen
JAMA Network Open · 03.04.2026 · 9 (4) · e262289
DOI: 10.1001/jamanetworkopen.2026.2289 ↗Auf einen Blick
In einer Phase-2-RCT war CN-105 nach Operationen machbar und erhöhte unerwünschte Ereignisse nicht. Delir und Delirseverity waren unter CN-105 numerisch niedriger, aber nicht signifikant.
Fragestellung
Ist CN-105 bei älteren Patient:innen nach nichtkardialer oder nichtintrakranieller Operation sicher und machbar, und beeinflusst es Delir und Neuroinflammation?
Methode
Triple-blind, eskalierende Dosis, Phase-2-RCT; 60 Jahre oder älter; CN-105 i.v. oder Placebo; primärer Endpunkt Sicherheit.
Ergebnisse
186 randomisierte Patient:innen. Unerwünschte Ereignisse Grad 2 oder höher: 76,6 % vs. 87,8 %; RR 0,87 (95 %-KI 0,76–1,00). Delir: 19,3 % vs. 26,5 %; OR 0,66 (95 %-KI 0,31–1,42).
Schlussfolgerung der Autor:innen
CN-105 war in dieser Phase-2-RCT machbar und erhöhte unerwünschte Ereignisse nicht. Eine Phase-3-Studie zur Wirksamkeit und zu Delirendpunkten ist laut Autor:innen angezeigt.
Kernaussagen
- CN-105 war machbar und schien sicher
- Delir numerisch seltener, aber nicht signifikant
- Phase 3 soll Wirksamkeit und Delir genauer prüfen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 03.04.2026. Verfasst von Noah J Timko und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina. Hauptthemen laut MEDLINE: Delirium, Postoperative Complications, Apolipoproteins E, Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Delir
Abstract (Originalsprache)
Importance The apolipoprotein E ( APOE ) gene ε4 allele leads to increased Alzheimer disease risk and neuroinflammation and is also believed to play a role in postoperative delirium. However, the safety and feasibility of modulating apoE protein signaling to reduce postoperative neuroinflammation and delirium in older adults are unclear.
Objective
To assess the safety and feasibility of the apoE mimetic peptide CN-105 for reducing delirium incidence and severity and neuroinflammation after noncardiac or nonintracranial surgery in older adults. Design, Setting, and Participants This triple-blind, escalating dose, phase 2 randomized clinical trial enrolled patients from April 17, 2019, to December 28, 2022, at a tertiary academic medical center. Included patients were 60 years or older and scheduled for a noncardiac or nonintracranial surgery. Exclusion criteria were incarceration, planned chemotherapy within 6 weeks after surgery, or inability to undergo lumbar punctures. Data analyses were based on a modified intention-to-treat approach and were performed from August 14, 2023, to August 22, 2025.
Interventions
Patients were randomly assigned 3:1 to the CN-105 group or placebo group. The CN-105 group received intravenous CN-105 doses of 0.1, 0.5, or 1 mg/kg starting within 1 hour before surgery and administered every 6 hours afterward until hospital discharge or 13 doses were received. Patients in the placebo group followed the same administration schedule. Main Outcomes and Measures The primary outcome was safety—the incidence and number of postoperative adverse events (AEs). Secondary outcomes included feasibility (rate of drug doses administered within 90 minutes of schedule), postoperative delirium incidence and severity, and postoperative changes in cerebrospinal fluid (CSF) cytokine levels (interleukin [IL] 6, granulocyte-colony stimulating factor [G-CSF], monocyte chemoattractant protein-1 [MCP-1], and IL-8).
Results
Among 203 enrolled patients, 186 (mean [SD] age, 68.7 [5.2] years; 119 males [64.0%]) were randomized (137 to the CN-105 group, 49 to the placebo group) and underwent surgery. The rates of grade 2 or higher AEs among patients in the CN-105 and placebo groups were 76.6% and 87.8% (relative risk [RR], 0.87; 95% CI, 0.76-1.00; P = .10). The CN-105 vs placebo group had fewer grade 2 or higher AEs per patient (median [IQR], 1 [1-3] vs 2 [1-5]; P = .03). The percentage of CN-105 doses administered within the time window was 94.6% (860 of 909; 95% CI, 92.9%-96.0%) in the CN-105 group and 93.8% (346 of 369; 95% CI, 90.8%-96.0%) in the placebo group. Among patients in the CN-105 vs placebo group, the postoperative delirium incidence was 19.3% vs 26.5% (odds ratio [OR], 0.66; 95% CI, 0.31-1.42; P = .29); the median (IQR) postoperative delirium severity scores were 1 (1-2) vs 2 (1-2) ( P = .19); and the median difference in preoperative to 24-hour postoperative CSF cytokine-level changes were as follows: −0.39 pg/mL (95% CI, −0.93 to 0.14 pg/mL, P = .12) for IL-6, −0.84 pg/mL (95% CI, −3.06 to 1.40 pg/mL; P = .18) for G-CSF,−23.32 pg/mL (95% CI, −94.36 to 44.93 pg/mL; P = .57) for IL-8, and −2.36 pg/mL (95% CI, −58.57 to 58.62 pg/mL; P = .50) for MCP-1. Conclusions and Relevance In this phase 2 randomized clinical trial of older surgical patients, CN-105 (vs placebo) administration was feasible and did not increase AEs. A phase 3 trial is warranted to further evaluate the efficacy of CN-105 for reducing postoperative AEs and to more precisely determine its effects on postoperative delirium incidence and severity. Trial Registration ClinicalTrials.gov Identifier: NCT03802396
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina.
- Now with Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, California.
- Duke University School of Medicine, Durham, North Carolina.
- Center for Cognitive Neuroscience, Duke University Medical Center, Durham, North Carolina.
- Duke Institute for Brain Sciences, Duke University, Durham, North Carolina.
- Department of Psychology and Neuroscience, Duke University, Durham, North Carolina.
Förderung
- NIA NIH HHS
Zitieren
APA
Timko, N. J., Cooter Wright, M., Smith, M. R., Boykin, P. C., Emerson, J. M., Woldorff, M. G., Eleswarpu, S., Herbert, J. T., Moretti, E. W., Devinney, M. J., Ayoub, C. M., Rockhold, F. W., Ryu, D., Syed, A., VanDusen, K. W., Bunning, T., Hsia, B. J., Bolognesi, M. P., Jiranek, W. A., …, & MARBLE Study Investigators (2026). Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients. JAMA Network Open, 9(4), e262289. https://doi.org/10.1001/jamanetworkopen.2026.2289
Vancouver
Timko NJ, Cooter Wright M, Smith MR, Boykin PC, Emerson JM, Woldorff MG, et al. Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients. JAMA Network Open. 2026;9(4):e262289. doi:10.1001/jamanetworkopen.2026.2289
BibTeX
@article{Timko2026,
author = {Timko, Noah J and Cooter Wright, Mary and Smith, Melody R and Boykin, Piper C and Emerson, Jacqueline M and Woldorff, Marty G and Eleswarpu, Sarada and Herbert, J Taylor and Moretti, Eugene W and Devinney, Michael J and Ayoub, Chakib M and Rockhold, Frank W and Ryu, David and Syed, Ayesha and VanDusen, Keith W and Bunning, Thomas and Hsia, Bethany J and Bolognesi, Michael P and Jiranek, William A and Zetterberg, Henrik and Blennow, Kaj and Huebner, Janet L and Li, Zhong and Reekes, Tyler H and Browndyke, Jeffrey N and Laskowitz, Daniel T and Berger, Miles and MARBLE Study Investigators, MARBLE Study Investigators},
title = {Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {4},
pages = {e262289},
doi = {10.1001/jamanetworkopen.2026.2289}
}
EUVIMED